Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

oint, with the regression analysis indicating a highly statistically significant dose response (p<0.0001).

Additional efficacy results are as follows: Mean Serum Phosphorus (mg/dL) ITT (n=146)1g/Day
(n=50)6g/Day
(n=51)8g/Day
(n=45)Baseline (End of Washout)

7.3

7.6

7.5Day 28/LOCF* (End of Treatment)

7.4

5.6

5.3Change from Baseline at Day 28

P-Value

0.1-2.0

<0.0001

-2.2

<0.0001% Change from Baseline at Day 28

0.5%

-25.7%

-29.6%* Last observation carried forward was used for missing data.

Additional highlights from Dr. Goldfarb's presentation on Zerenex are as follows:

  • Statistically significant dose response increase in serum bicarbonate suggests potential to address metabolic acidosis
  • Statistically significant dose response reduction in calcium x phosphorus product
  • Modest upward trends in Ferritin and TSAT in 6 grams/day and 8 grams/day dose groups further supports theory that Zerenex could reduce the need for intravenous iron and erythropoiesis-stimulating agent (ESA) use
  • Zerenex appeared to be safe and well-tolerated in the study
  • GI adverse events were mostly mild and transient in nature
  • No SAEs were deemed to be drug-related by the Data Safety Monitoring Committee

  • Dr. Goldfarb concluded that Zerenex has the potential to become a viable alternative to the currently approved phosphate binders used to treat ESRD patients.

    Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are encouraged by the final efficacy and safety data from the Phase 3 short term study presented earlier today, which confirm the top-line data previously reported."  Mr. Bentsur continued, "We thank Dr. Goldfarb for his time and effort in preparing for and delivering this morning's presentation."

    In accordance with the Company's Special Pr
    '/>"/>

    SOURCE Keryx Biopharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
    2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
    3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
    4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
    5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
    6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
    7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
    8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
    9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
    10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
    11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
    (Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
    (Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
    (Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
    Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
    ... BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a ... today announced that it has received notification from The ... been approved for listing on the NASDAQ Global Market. ... 2009 on NASDAQ at market open under the symbol ...
    ... 6 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a ... today announced it has received US$2,500,000 from MannKind ... the option agreement and issuance of 2,400,000 units ... The transaction provides MannKind with the option to ...
    ... Star Scientific (Nasdaq :STSI) announced today that its ... its Star Tobacco, Inc. subsidiary, recently completed a ... dissolvable smokeless tobacco to relieve cigarette withdrawal symptoms ... (NRT). The study, which included 49 cigarette smokers, ...
    Cached Biology Technology:BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 2Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 4
    (Date:4/15/2014)... Biologists at UC San Diego have succeeded in ... hormone responsible for growth and resistance to drought. ... studies to determine how the hormone helps plants ... by the continuing increase in the atmosphere,s carbon ... achievement appears in the April 15 issue of ...
    (Date:4/15/2014)... Looking at the question of how social behavior has ... universities in Mainz and Basel have gained new insights ... simply compete for food. Rather the siblings share what ... absent," explained Dr. Jol Meunier of the Evolutionary Biology ... University of Mainz (JGU). The team of biologists from ...
    (Date:4/15/2014)... (April 15, 2014) The American Association of Anatomists ... All awards will be presented during the Closing ... Hotel on Tuesday, April 29th at 7:30 p.m. during ... , The 2014 award winners are: , ... PhD, of the Icahn School of Medicine at Mount ...
    Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Sibling cooperation in earwig families gives clues to early evolution of social behavior 2American Association of Anatomists 2014 award winners 2
    ... Spanish scientists have analysed the temperature and salt levels of ... the evolution of each variable. Their research shows that, since ... hotter and saltier, and that, since the 1990s, this process ... deep layer of the Western Mediterranean increases by 0.002C, and ...
    ... Miami (UM) has been selected to receive a $1.4 ... to strengthen the UM undergraduate science education program. The ... will use the resources to help attract first-generation college ... sciences to pursue careers in science. , "HHMI ...
    ... of Oxford and Royal Holloway University of London have discovered that ... works best if applied to young plants and is enhanced by ... (20 May) in the open-access journal PLoS Pathogens . ... is a common method for controlling a variety of insect ...
    Cached Biology News:Temperature and salt levels of the Western Mediterranean are on the increase 2UM receives 5th consecutive Howard Hughes Medical Institute grant for science education 2Study uncovers optimal ecology of bioinsecticide 2
    ...
    Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
    ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
    Mouse monoclonal antibody to FMN2 - formin 2...
    Biology Products: